YWYu-Xin Wang

Yu-Xin Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu-Xin Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Bohan Zhang

    Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

    1 shared publication
  • Cheng Liu

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China

    1 shared publication
  • Da-Li You

    1 shared publication
  • Donghe Yu

    Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

    1 shared publication
  • Erke Gao

    Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

    1 shared publication
  • Fei Wang

    Shanghai University of Medicine & Health Sciences, Shanghai University of Traditional Chinese Medicine, China

    1 shared publication

Latest Publications

  • Open Access

    Diagnostic Model for Type 2 Myocardial Infarction in Sepsis Patients: Development and Multicenter Validation in the ICU Setting (Preprint)

    by Yue Li, Yu-Xin Wang, Wu-Lin Li, Xiao-Ya Ma, Xiao Han, Li-Li Zhu, Sai-Bei Wang, Na-Na Fan, Yun-Yue Luo, Da-Li You, et al.

    BACKGROUND Type 2 myocardial infarction (T2MI), caused by a mismatch in myocardial oxygen supply and demand, is a common complication in sepsis patients. However, its diagnosis remains challenging due to non-specific clinical presentations and the difficulty in distinguishing it from other causes of troponin elevation. This diagnostic ambiguity creates an urgent need for reliable diagnostic tools, especially since the management of T2MI fundamentally differs from that of type 1 MI. OBJECTIVE To develop, validate, and evaluate a diagnostic model for type 2 myocardial infarction in sepsis patients. METHODS Model development and internal validation were conducted using data from sepsis patients in the Medical Information Mart for Intensive Care IV database. External validation was performed on the intensive care unit patients of Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences. Variables were selected using backward elimination. Then, they were incorporated into a logistic regression model to construct the diagnostic score. Discriminative ability and calibration were evaluated by the area under the receiver operating characteristic curve and calibration curves, respectively; prediction results were displayed using a nomogram and forest plots. RESULTS The derivation cohort included 2,519 patients and was divided into a training set (n=1,763) and a test set (n=756). External validation was performed on a separate cohort of 70 patients. Multivariate logistic regression identified the following independent factors associated with T2MI: diabetes mellitus, coronary heart disease, respiratory failure, old myocardial infarction, acute respiratory distress syndrome, septic shock, invasive mechanical ventilation, blood urea nitrogen, prothrombin time, international normalized ratio, temperature, and age. The final model achieved an AUC of 0.81 (95% CI: 0.79–0.83) in the training set, 0.79 (95% CI: 0.76–0.83) in the test set, and 0.78 (95% CI: 0.65–0.91) in the external validation cohort. The calibration curves showed excellent agreement between the predicted and observed probabilities across all datasets, indicating good model calibration. Sensitivity, specificity, positive predictive value, and negative predictive value were consistently high across all datasets. CONCLUSIONS The developed T2MI diagnostic scoring system for sepsis patients demonstrated strong discrimination and calibration, accurately predicting T2MI risk and proving useful for clinical diagnosis. CLINICALTRIAL none

  • Open Access

    Comparison of immune checkpoint inhibitors in combination with chemotherapy versus chemotherapy alone in the first-line treatment of advanced gastric cancer patients with low PD-L1 expression: a systematic review and meta-analysis

    by Yuxin Wang, Tong Xie, Shuai Xiang, Cheng Liu, Siyuan Cheng, Bohan Zhang, Yifan Zhang, Yang Feng, Yingxuan Wang, Donghe Yu, et al.

    Background: Immune checkpoint inhibitors (ICIs) + chemotherapy became standard her2-GC first line treatment. Objectives: The aim of this study is to investigate whether ICIs + chemo provides benefit for patients with low programmed death-ligand 1 (PD-L1) expression. Design: This study is a systematic review and meta-analysis. Data sources: We searched PubMed, Embase, Web of Science, and Cochrane Library as well as the 2019 to 2024 Annual Meetings of the European Society for Medical Oncology, the American Association for Cancer Research, the American Society of Clinical Oncology (ASCO), and the ASCO Symposium on Gastrointestinal Oncology (ASCO-GI) and the ClinicalTrials.gov database. Methods: This systematic review included phase III randomized controlled trials comparing first-line immunotherapy combined with chemotherapy versus chemotherapy alone in advanced gastric cancer. KMSubtraction was used to estimate survival data for those trials that did not report data for the PD-L1 low-expression population. Results: We included a total of nine randomized clinical trials. In patients with combined positive score (CPS) < 1 and CPS < 5, monoclonal antibody + chemotherapy did not show an improvement in overall survival (OS) or progression-free survival (PFS) (CPS < 1 OS: hazard ratio (HR) = 0.91, 95% CI: 0.77–1.08; PFS: HR = 0.88, 95% CI: 0.73–1.07. CPS < 5 OS: HR = 0.92, 95% CI: 0.79–1.08; PFS: HR = 0.78, 95% CI: 0.53–1.14). However, in trials using dual antibodies, patients with PD-L1 CPS < 5 achieved improvements in PFS (HR = 0.64, 95% CI: 0.52–0.80). In trials using tumor area positivity (TAP) scoring, the subgroup with TAP < 5% did not achieve benefits in OS or PFS from immunotherapy plus chemotherapy (OS: HR = 0.92, 95% CI: 0.75–1.13; PFS: HR = 0.91, 95% CI: 0.74–1.13). Conclusion: Our study results indicate that in the first-line treatment of advanced gastric cancer, monoclonal antibody combined with chemotherapy does not provide a survival benefit compared to chemotherapy alone for patients with low PD-L1 expression. However, it is noteworthy that in the COMPASSION-15 trial, patients with CPS < 5 achieve significant improvements in OS and PFS, which may be related to the bispecific antibodies and needs to be validated by further studies. Trial registration: This study was registered in PROSPERO (CRD42024568972).